Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
about
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyActivation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)Dual roles of yes-associated protein (YAP) in colorectal cancer.Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).The combination of checkpoint immunotherapy and targeted therapy in cancer.TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3.Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.YAP regulates PD-L1 expression in human NSCLC cells.Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.Tumour heterogeneity and resistance to cancer therapies.TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
P2860
Q38598893-E0ECCE44-76E5-4F85-B23D-FA5F61AAFF34Q41471047-2E04ADEE-2F17-4F9B-A326-BFACBEED422EQ43651454-7AA3D5B4-1976-4C29-9E94-2C3B18EB5F52Q43991475-C7A6ACD4-CCFC-4792-A252-202C7336D1B6Q45822425-B5669643-5A2B-4D2D-974F-832D9A7596EEQ47100314-42483A31-546E-4536-8BFB-21F4AD277AF2Q47828321-86597222-E6A7-4C96-AC1B-B4591C9945BEQ49340076-15E92003-7B12-45C4-B929-17521A31D460Q49501422-40157CE4-4785-4141-88DA-C4497796100DQ49569691-04C75057-7D22-459B-BD5B-5232E8B6BE08Q50056486-5249C4FD-60C1-4D07-A399-5744F07E11A7Q50112440-C4610810-751A-4CC2-8FCC-60C38D2F1BF4Q52317261-B4C5AA65-7203-406E-89C5-8783DEF7A611Q52317592-C0E9D726-1EA8-4423-8246-FB218C5BB1C4Q54939484-62E2D827-45A6-458C-9D5B-1ED56E23C7B5Q55314894-FC0C6688-03FA-4668-BD17-EA935A84655B
P2860
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
description
2017 nî lūn-bûn
@nan
2017 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@ast
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@en
type
label
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@ast
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@en
prefLabel
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@ast
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@en
P2093
P2860
P50
P356
P1476
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
@en
P2093
Alain Vergnenegre
Alberto Verlicchi
Ana Drozdowskyj
Andres Felipe Cardona
Caicun Zhou
Carles Codony Servat
Charo Garcia Campelo
Chiara Lazzari
Christina Teixido
Chunping Hu
P2860
P356
10.1093/JNCI/DJX014
P407
P50
P577
2017-09-01T00:00:00Z